Altimmune Inc (ALT)

$2.60 0.10 (4.00%)

16:00 EDT ALT Stock Quote Delayed 30 Minutes

The 3 Most Promising Biotech Innovations in 2023 and the Stocks to Buy

By Chris Markoch, InvestorPlace Contributor Apr 28, 2023

Here are three biotech companies with promising innovations that could provide catalysts for their respective stocks in 2023

7 Biotech Stocks With Huge Return Potential for Long-Term Investors

7 Cheap Stocks That Are Worth Your Attention

Why Is Altimmune (ALT) Stock Down 67% Today?

Volume:

Previous Close -

Market Cap 136.98M

PE Ratio -1.60

EPS -1.63

Volume (Avg. Vol.) 984,938

Day's Range $2.50 - $2.65

52-Week Range $2.34 - $17.17

Dividend & Yield N/A (N/A)

ALT Stock Predictions, Articles, and Altimmune Inc News

From InvestorPlace
From the Web

7 Small-Cap Stocks with Big Growth Potential in 2023

By Ian Cooper, InvestorPlace Contributor Jan 10, 2023

Some of the greatest opportunities can be found in these small-cap stocks to buy. For one, a good number of small-cap stocks are severely undervalued.....

The 7 Hottest Biotech Stocks to Own in 2023 and Beyond

By Ian Cooper, InvestorPlace Contributor Dec 18, 2022

Some of the hottest biotech stocks are safe and recession-proof. After all, we can’t stop people from aging – at least, not yet. We can’t....

Altimune (ALT) Stock Plummets 33% Despite Positive Clinical Data

By William White, InvestorPlace Writer Sep 14, 2022

Altimune (ALT) stock is falling hard on Wednesday even after reporting positive results from a Phase 1b clinical trial this morning.

7 Biotech Stocks to Buy for Q3

By Shanthi Rexaline Jul 18, 2022

These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential.

ALT Stock: One Analyst Still Thinks Altimmune Prices Could Hit $34

By Samuel O'Brient, InvestorPlace Financial News Writer Sep 28, 2021

Some clinical trial results released by Altimmune have shareholders rushing to sell. But, one analyst sees plenty of upside for ALT stock.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer Jun 30, 2021

Good morning! We're taking a look at the biggest pre-market stock movers for Wednesday and that includes the winners and losers.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

By William White, InvestorPlace Writer May 10, 2021

Get ready for another busy week of trading as we kick off Monday with a look at the biggest pre-market stock movers for today.

2020 In Review — 9 Great (And Not-So-Great) Calls

By Chris Lau, InvestorPlace Contributor Jan 6, 2021

Technology and biotech stocks brought in more winning picks than usual, thanks partly to the strong stock market. Here are some of my best calls.

Altimmune Earnings: ALT Stock Rises 7% Despite Rough Q2 Results

By Nick Clarkson, Web Editor Aug 12, 2020

Altimmune earnings from Tuesday evening have ALT stock higher despite the company reporting rough figures for second quarter of FY2020.

Altimmune Earnings: ALT Stock Tumbles 12% on FY Miss

By William White, InvestorPlace Writer Mar 27, 2020

Altimmune (ALT) earnings for the biopharmaceutical company's fiscal year of 2019 have ALT stock taking a dive Friday after missing estimates.

Altimmune Stock Has Major Pipeline Potential

By Louis Navellier and the InvestorPlace Research Staff Mar 18, 2020

There's no guarantee of a coronavirus cure, but Altimmune stock is worth owning on hopes of an effective vaccine.

Altimmune News: ALT Stock Rockets 110% on Coronavirus Vaccine News

By William White, InvestorPlace Writer Feb 28, 2020

Altimmune (ALT) news for Monday includes positive news about a vaccine to treat the coronavirus from China have ALT stock soaring higher.

Altimmune News: ALT Stock Skyrockets on Positive Flu Vaccine Data

By William White, InvestorPlace Writer Mar 19, 2019

Altimmune news concerning the results from a Phase 2 extension study of the company's NasoVAX has ALT stock heading higher today.

Why Altimmune Stock Is Sliding Lower Today

By William White, InvestorPlace Writer Oct 8, 2018

Altimmune stock was falling hard Monday on news that the company is selling additional stock to investors in a new offering.

Why Altimmune Stock Is Skyrocketing Today

By Karl Utermohlen, InvestorPlace Writer Sep 19, 2018

Altimmune stock (ALT) soared more than 285% following successful clinical trial data of a medication and a reverse split of common shares.

Should You Buy Viking Therapeutics Stock After It Skyrocketed Over 60%?

From The Motley Fool Mar 29, 2023

Viking could have a strong rival to Novo Nordisk's Wegovy and Ozempic and Lilly's Mounjaro in the making.

Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data

From MarketBeat Mar 28, 2023

Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP

Is Viking Therapeutics a Smart Buy on the Dip?

From The Motley Fool Mar 27, 2023

The stock recently fell around 25% for reasons that had nothing to do with its lead program.

ALT stock falls as Goldman Sachs downgrades on weight loss data (NASDAQ:ALT)

From Seeking Alpha Mar 22, 2023

Altimmune (ALT) shares plunged to a 10-month low as Goldman Sachs downgraded it citing early-stage data for the company’s weight loss candidate pemvidutide. Read the full story here.

Wall Street Absolutely Loved This Biotech Stock. But It Just Crashed More Than 50%.

From The Motley Fool Mar 22, 2023

It's not the end of the story for this once high-flying biotech stock.

Altimmune (ALT) Gets a Buy from JMP Securities

From TipRanks Dec 5, 2022

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Altimmune (ALT – Research Report) today and set a price target of $26.00. The c...

Altimmune Inc (ALT)

The 3 Most Promising Biotech Innovations in 2023 and the Stocks to Buy

7 Biotech Stocks With Huge Return Potential for Long-Term Investors

7 Cheap Stocks That Are Worth Your Attention

Why Is Altimmune (ALT) Stock Down 67% Today?

11 Best Stocks to Buy for 2023

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Altimmune Inc (ALT)

11 Best Stocks to Buy for 2023

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

ALT Stock Predictions, Articles, and Altimmune Inc News

Subscriber Sign in